News
ALKS
29.70
-1.13%
-0.34
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
NASDAQ · 2d ago
Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)
TipRanks · 2d ago
Weekly Report: what happened at ALKS last week (0219-0223)?
Weekly Report · 2d ago
Alkermes downgraded at UBS as stock nears 52-week high
UBS has downgraded Alkermes to sell from hold. The firm has a price target of $25. The stock is up 12% over the last year. UBS sees a negative risk/reward following a pipeline update and disappointing sales of Rybalvi.
Seeking Alpha · 02/20 17:32
Weekly Report: what happened at ALKS last week (0212-0216)?
Weekly Report · 02/19 09:08
Hold Rating on Alkermes Amid Competitive Uncertainty and Limited Growth Prospects
Alkermes (ALKS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 15. Leerink Partners maintained a Hold rating on the stock and has a $30.00 price target. The company’s fourth-quarter performance and 2024 guidance were solid.
TipRanks · 02/19 04:46
Notable Friday Option Activity: CMP, ALKS, JPM
NASDAQ · 02/16 20:30
Small cap value stocks with potential M&A candidacy - BofA
BofA Securities has updated its small-cap value stocks that are potential mergers and acquisitions candidates. The small cap value stocks are from the Russell 2000. Mergers and deals have picked up in several sectors, particularly in health care. There is more potential for sectors such as staples and banks.
Seeking Alpha · 02/16 16:10
Piper Sandler Remains a Buy on Alkermes (ALKS)
TipRanks · 02/16 12:38
Alkermes: Hold Rating Affirmed Amid EBITDA Growth and Strategic Acquisitions, Balanced by Cautious Sales Outlook
TipRanks · 02/16 10:09
Alkermes: A Strong Buy on Path to Profitability, Strategic Capital Allocation, and Pipeline Momentum
TipRanks · 02/16 02:35
Health Care Sector Update for 02/15/2024: AUPH, ALKS, WST
NASDAQ · 02/15 19:04
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
NASDAQ · 02/15 18:34
Thursday's ETF with Unusual Volume: FBT
NASDAQ · 02/15 17:11
Compared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key Metrics
NASDAQ · 02/15 14:30
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.